AEON Biopharma (AEON) Proxy Filing summary

Executive summary

• Special Meeting scheduled for February 24, 2025, to vote on four key proposals, including increasing authorized shares, a reverse stock split, warrant issuance, and potential adjournment to solicit more proxies.

• Board recommends approval of all proposals to provide flexibility for future financings, maintain NYSE American listing, and comply with listing rules.

• Forward-looking statements highlight potential risks and uncertainties regarding future operations and financial performance.

Voting matters and shareholder proposals

• Proposal 1: Increase authorized common stock from 500,000,000 to 1,040,000,000 shares to support future financings, acquisitions, and corporate purposes.

• Proposal 2: Authorize a reverse stock split at a ratio between 1-for-5 and 1-for-150, at the Board's discretion, to maintain NYSE American listing and improve share price.

• Proposal 3: Approve issuance of warrants and underlying shares related to a January 2025 offering, in compliance with NYSE American rule 711.05.

• Proposal 4: Approve adjournment of the meeting if more time is needed to solicit proxies for the above proposals.

Board of directors and corporate governance

• Board unanimously recommends voting FOR all proposals.

• No director or executive officer has a substantial interest in any proposal beyond that of other stockholders.